Taken together, this prospective clinical study of patients with RA demonstrated that serum SAA levels can be changed by antirheumatic drugs, most strikingly by Tocilizumab, an inhibitor of SAA-stimulating cytokine IL-6, presumably reflecting RA activity and therapeutic outcome. Here, SAA1 is linked to rheumatoid arthritis.